Holostem at the second asset talk organised by Clust-ER Health
On Thursday 3 June, the second event dedicated to the exploration of the assets identified during 2020 in the in-depth analysis of the potential and prospective attractiveness carried out on the health and wellness sector in Emilia-Romagna will be held. The theme of this meeting, which will start at 5 p.m., is advanced therapies: technically called ATMPs (Advanced Therapy Medicinal Products), they are therapies based on cells, tissues and genetic material that are revolutionising regenerative medicine, offering new tools for treating diseases and tissue damage.
In 2019, the ATMPs market consisted of 34% cell therapies, 3% gene therapies and 63% tissue engineering. In 2025, the market will see an increase in the importance of cell and gene therapies, at the expense of tissue engineering: 42% of the market will be cell-based therapies, 14% gene-based therapies and only 44% tissue engineering. The market value of ATMPs will increase dramatically from around €26 billion in 2019 to an estimated €130 billion in 2025, with a growth rate of 33% over the period 2020-2025.
During the event, the situation in Emilia-Romagna and the innovation and development strategies implemented by regional stakeholders will be discussed. The participants will be the members of Clust-ER Health, including laboratories, inter-departmental centres and companies involved in this field, and will tell through their experiences the trends, investments and prospects for innovation at national and international level. In addition to Holostem, represented by Marco Dieci (CEO), Stem Sel, Comecer, Istituto per la cura dei Tumori di Meldola and LTTA will also participate in the round table.
- Newcastle pharmacy experts work with Italian biotech lab to provide access to sight-saving treatment across England
- Holostem Terapie Avanzate begins its transition to a Foundation
- Transgenic Epidermal Cultures for Junctional Epidermolysis Bullosa — 5-Year Outcomes
- Gene therapy for butterfly children: 5-year follow-up published in the New England Journal of Medicine
- Hologene 5: A Phase II/III Clinical Trial of Combined Cell and Gene Therapy of Junctional Epidermolysis Bullosa